Merck & Co posts mixed 1st-qtr 2014 results
US pharma giant Merck & Co (NYSE: MRK) today reported first-quarter 2014 adjusted diluted earnings per share (EPS) of $0.88, up from $0.85, and revenues of $10.26 billion, down 3%. Merck’s shares gained 3.05% to $58.44 in mid-morning New York trading.
EPS beat consensus analysts’ estimates of $0.79 but sales missed forecast of $10.44 billion, according to Thomson Reuters. Non-generally accepted accounting principle (GAAP) net income came in at $2.60 billion, a slight rise of 0.6%.
Pharmaceutical sales took a 3% hit from currency exchange rates and total drug sales were down 5% from $8.89 billion to $8.45 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze